echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Top 100 innovation capacity of listed enterprises in China's pharmaceutical and health industry in 2018

    Top 100 innovation capacity of listed enterprises in China's pharmaceutical and health industry in 2018

    • Last Update: 2019-05-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical and health industry is knowledge intensive, technology intensive, talent intensive and capital intensive, and its essence is R & D driven industry In recent years, China's pharmaceutical and health industry has maintained a rapid growth, and R & D investment has continued to increase By the end of 2018, there were 299 listed enterprises in China's pharmaceutical and health industry (small and medium-sized board, growth enterprise board, and main board listed enterprises), covering seven major fields, including biotechnology, western medicine, traditional Chinese medicine, life science tools and services, health care services, medical and health equipment and medical and health supplies, It covers 30 provinces and cities In 2018, the total assets scale of Chinese medical and health listed enterprises reached 1981.099 billion yuan, the total operating revenue was 1403.561 billion yuan, and the net profit was 109.041 billion yuan Among them, R & D expenditure totaled 44.537 billion yuan, a year-on-year increase of 34.72%, accounting for 3.17% of the operating revenue of all listed enterprises At the same time, the R & D expenditure of top 100 innovative enterprises totaled 25.263 billion yuan, accounting for 56.72% of the total R & D expenditure of listed pharmaceutical and health enterprises Sina pharmaceutical and CCID Consulting have combed 299 listed pharmaceutical and health enterprises that have published their 2018 annual reports as of May 7, 2019, ranked them according to the proportion of R & D expenditure of listed enterprises in the main business income ("total R & D expenditure / main business income"), forming the "top 100 innovation ability of listed pharmaceutical and health enterprises in China in 2018" The purpose of this list is to explore the investment opportunities of the pharmaceutical and health industry through the analysis and comparison of the secondary market, help enterprises understand the overall situation of the industry, and help investment institutions find potential investment depressions In 2018, the innovation ability of listed enterprises in China's pharmaceutical and health industry was the top 100 The first point of the list: the innovation ability of main board enterprises was significantly improved Although among the top 100 innovative enterprises, gem enterprises are the most, with 46 shortlisted, 24 shortlisted on the small and medium-sized board, and only 30 on the main board However, in terms of the proportion of R & D expenditure, the main board enterprises spent a total of 12.752 billion yuan, accounting for 50.48% of the total R & D expenditure of top 100, an increase of 2.07% compared with 2017 Point 2: Western medicine and Biotechnology R & D expenditure is the largest Top 100 innovative enterprises are mainly concentrated in western medicine and biotechnology Meanwhile, among the top 100 innovative enterprises in 2018, the R & D expenditure of Western medicine enterprises totaled 15.093 billion yuan, accounting for 59.74% of the total R & D expenditure of top 100 The R & D expenditure of life science tools and services is the least, accounting for only 0.05% of the total R & D expenditure of top 100 In 2018, the R & D expenditure of top 100 innovative enterprises listed in the pharmaceutical health sector will continue to grow From the perspective of regional agglomeration, most of the top 100 innovative enterprises are concentrated in Guangdong, with 23 shortlisted, and the agglomeration effect is obvious In terms of the growth in the number of innovative enterprises, Shandong and Hunan have the fastest growth, with 5 enterprises in Shandong shortlisted, 4 more than in 2017; 4 enterprises in Hunan shortlisted, 2 more than in 2017, 3 more than in 2016 From the perspective of the stability of the number of innovative enterprises, the number of enterprises in Jiangsu Province has fluctuated greatly in the past three years In 2018, 7 enterprises were shortlisted, 3 less than that in 2017, 2 less than that in 2016; the number of innovative enterprises in Sichuan, Beijing, Shanghai and other provinces and cities has not changed, which is relatively stable; the number of innovative enterprises in Tibet, Guizhou, Chongqing, Heilongjiang, Xinjiang and other five provinces and regions has continued to decrease Point 4: innovation contributes significantly to market value In 2018, the total market value of medical and health listed enterprises was 308224 million yuan, a year-on-year decrease of 20.55%; the total market value of top 100 innovative enterprises was 1184.257 billion yuan, a year-on-year decrease of 17.28% However, in 2018, the total market value of top 100 innovative enterprises accounted for 38.42% of the total market value of 299 listed pharmaceutical and health enterprises, and it has maintained stable growth in the past three years, which shows that innovation is the foundation of pharmaceutical and health enterprises, while improving the competitiveness of enterprises, enhancing the anti risk ability of enterprises in the capital market Point 5: the profitability of innovative enterprises continues to increase On the one hand, from the growth of net profit, only 9 of the top 100 enterprises have negative net profit Among them, there are two top 10 innovative enterprises in top 100, namely Jiuan medical (fourth) and Haili Biology (eighth) On the other hand, in terms of profitability, 2 of the top 100 most profitable enterprises spent R & D in the top 100 innovative enterprises in 2018 2、 Point of view 1: the R & D innovation model of enterprises has changed from closed to open, and win-win cooperation has become a consensus First, with the acceleration of globalization, the increasingly fierce competition among enterprises, the frequent iteration of new technologies, the acceleration of information dissemination and the reduction of communication costs; second, cooperation at different levels, from strategic level, project level to authorized patent level, has become an important means for the rapid development of enterprises; third, with the transformation of knowledge industrialization, resource capitalization and asset securitization in the future, VC R & D mode composed of VC / PE, IP and cdmo will become the mainstream Point 2: the national regulatory mechanism has changed from re examination and approval to re regulation, focusing on compliance risk On the one hand, "healthy China" has become a national strategy National ministries and commissions and major regulatory departments have continuously increased industrial support, the drug registration and approval system has been continuously optimized, the "4 + 7" City drug centralized procurement pilot, the establishment of MAH and other systems have further promoted the overall development of the medical and health industry from imitation to innovation On the other hand, with the continuous increase of industry supervision, industry compliance issues are highlighted The financial doubts of Kangmei pharmaceutical industry, the fraud of Changsheng biological vaccine, Fosun Pharmaceutical falling into the "reporting gate", and valsartan of Huahai pharmaceutical industry, etc have constantly impacted the capital market, causing the overall stock price of the medical health sector in the secondary market to continue to decline, suggesting that investors pay attention to the compliance risk of the target Point 3: the valuation system of an enterprise changes from financial investment to industrial value, focusing on potential value On the one hand, the investment of capital market in medical and health industry tends to be rational, conceptual projects and early projects gradually reduce, and gradually concentrate on innovative and excellent projects Strategic investment and M & a mainly by large enterprises are increasing, which promotes the overall innovation level of the industry On the other hand, the financial investment based valuation system has been unable to meet the financing needs of innovative enterprises in the pharmaceutical health industry, which conflicts with the essence of the pharmaceutical health industry Therefore, it will be the choice of more enterprises and investment institutions to look down on the whole industry from a higher perspective, understand the overall development trend, explore the internal logic, explore the potential value of enterprises, reasonably avoid risks, and build a valuation system based on industrial value.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.